Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.

ABSTRACT:

Background

Homologous recombination deficiency (HRD) is shown to predict response to DNA-damaging therapies in patients with high-grade serous ovarian cancer (HGSOC); however, changes in HRD during progression remains unknown.

Methods

HRD scores were evaluated in paired primary and/or recurrent HGSOC samples (N = 107) from 54 patients with adjuvant platinum-based chemotherapy. BRCA1/2 mutation, BRCA1 methylation, loss of heterozygosity (LOH), and HRD scores were characterised using tumour DNA-based next-generation sequencing assays.

Results

Among 50 evaluable pairs (N = 100 samples), high intra-patient correlation in HRD score was observed (r² = 0.93). BRCA1/2 mutations, BRCA1/2 LOH, and HRD were maintained between primary and recurrent samples, except for

SUBMITTER: Patel JN 

PROVIDER: S-EPMC6219476 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature